Newsletter Tool

PM Tracker

Today’s Big News

Mar 12, 2025

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset

J&J, Legend to invest $150M in Belgium cell therapy facility as new Carvykti rival looms

HHS closes six regional offices serving 32 states and territories

AbbVie regained TV ad spending lead amid February slowdown, with Rinvoq and Skyrizi back on top

Harbour BioMed launches new obesity biotech on mission to preserve muscle mass

Featured

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset

By Nick Paul Taylor

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipeline. The outlay, plus up to $3.6 billion in milestones, has secured Roche the right to codevelop and co-commercialize Zealand Pharma’s long-acting amylin analog petrelintide.

Johnson & Johnson CEO Joaquin Duato takes a 14% pay cut to $24.3M

By Kevin Dunleavy

In his third year as the CEO of Johnson & Johnson, Joaquin Duato received an overall compensation package of $24.3 million. It was a 14% decrease from his $28.4 million figure in 2023, when he was the highest-paid Big Pharma chief executive.

Insilico Medicine raises $110M for new trials and robotic helping hands

By Conor Hale

Insilico's series E round was led by Hong Kong-based firm Value Partners, and joined by Insilico’s previous investors plus unnamed first-time backers.

Ono pays $280M upfront for Ionis' antisense oligonucleotide for rare blood cancer

By James Waldron

Japan's Ono Pharmaceutical is paying $280 million upfront to acquire Ionis Pharmaceutical’s phase 2-stage antisense oligonucleotide for a rare type of blood cancer.

GSK posts data on HIV assets vying for roles in 6-month combo

By Nick Paul Taylor

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its plans to create a six-month regimen are shaping up.

Argenx's Vyvgart tops Trinity’s latest launch success analysis, beating out several Big Pharma debuts

By Andrea Park

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, according to the latest edition of Trinity Life Sciences’ annual Drug Index. The report looked at several factors to rank the industry's top launches from 2021.

J&J’s Monarch bronchoscopy robot cleared by FDA to connect to live CT scans

By Conor Hale

Dubbed Monarch Quest, the Nvidia-backed AI program can interface with GE HealthCare’s OEC 3D C-arm imaging system for live cone-beam CT navigation.

Canada's Entos Pharmaceuticals plots $137M R&D, manufacturing hub in Edmonton

By Zoey Becker

The facility will be used to develop and produce Entos' Fusogenix proteolipid vehicles (PLVs), which attracted Eli Lilly's interest for a partnership. The governments of Canada and Alberta are chipping in to help fund the site.

Fierce podcasts

Don’t miss an episode

'The Top Line': A look at biotech's biggest money raisers of 2024

This week on "The Top Line," we dig into several of the biggest private funding rounds in biotech last year and discuss the shifting VC landscape.

'The Top Line': Research reveals ‘ticking DNA clock’ behind Huntington’s disease

Podnosis: Ways providers can simplify patient billing

Resources

Whitepaper

The Oncology Market: 2025 Outlook

Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Redefining vaccine trial recruitment

Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials.

Sponsored by: Avacare Clinical Research Network

Whitepaper